News >

FDA Approves Brentuximab Vedotin for CTCL

Jason M. Broderick @jasoncology
Published: Thursday, Nov 09, 2017

The FDA has approved brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma (CTCL) who have received prior systemic therapy, according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication